首页 | 本学科首页   官方微博 | 高级检索  
     

前列腺癌免疫治疗中质粒pLenti6/V5-D-TOPO(R)-TβRⅡDNglytk构建的意义及相应慢病毒的产生
引用本文:杨阔,张婷,徐勇,畅继武,刘妍,张志宏. 前列腺癌免疫治疗中质粒pLenti6/V5-D-TOPO(R)-TβRⅡDNglytk构建的意义及相应慢病毒的产生[J]. 内分泌外科杂志, 2009, 3(5). DOI: 10.3760/cma.j.issn.1674-6090.2009.05.003
作者姓名:杨阔  张婷  徐勇  畅继武  刘妍  张志宏
作者单位:1. 天津市泌尿外科研究所,天津市泌尿外科重点实验室,天津,300211
2. 天津医科大学第二医院泌尿外科
基金项目:天津市科技汁划资助项目 
摘    要:目的 构建含有TβRⅡDNglytk的慢病毒质粒载体,生产出相应的慢病毒,用于对TGF-β失敏感的CTL的制备.方法 先以原始质粒为模板,PCR扩增TβRⅡDN和HSV-tk基因,用重组PCR方法获得TβRⅡDNglytk融合基因,用PCR扩增出TRANSglytk基因;再用TOPO克隆技术将其连接到慢病毒表达质粒,经测序验证;最后用Invitrogen公司提供的ViraPowerTM Lentiviral System和293FT细胞合成慢病毒,并用293细胞完成其滴度测定.结果 完成慢病毒质粒TβRⅡDNglytk的构建,经测序验证序列正确;生产的慢病毒具有感染能力,其滴度达到实验要求,可用于对TGF-β不敏感的肿瘤特异性CTL的制备.结论 运用重组PCR技术合成TβRⅡDNglytk及TRANSglytk两个融合基因,并用TOPO克隆技术连接到pLenti6/V5-D-TOPO(R)载体,成功构建了慢病毒表达载体,说明此方法用于病毒载体的构建是快捷可行的;用ViraPowerTM Lentiviral System和293FT细胞成功制备了慢病毒,为生产TGF-β不敏感的人肿瘤特异性CTL提供了基础.

关 键 词:前列腺癌  转化生长因子  慢病毒  肿瘤免疫治疗  基因转导  Transforming Growth Factor β

Construction of recombinant expression plasmid pLenti6/V5-D-TOPO(R)-TβRⅡDNglytk and production of the lentivirus in the immunotherapy for prostate cancer
YANG Kuo,ZHANG Ting,XU Yong,CHANG Ji-wu,LIU Yan,ZHANG Zhi-hong. Construction of recombinant expression plasmid pLenti6/V5-D-TOPO(R)-TβRⅡDNglytk and production of the lentivirus in the immunotherapy for prostate cancer[J]. , 2009, 3(5). DOI: 10.3760/cma.j.issn.1674-6090.2009.05.003
Authors:YANG Kuo  ZHANG Ting  XU Yong  CHANG Ji-wu  LIU Yan  ZHANG Zhi-hong
Abstract:Objective Our hypothesis was if we rendered host' s cytotoxic tumor lymphocytes insensitive to TGF-β,these immune cells could be able to overcome the TGF-β mediated immunosuppression and reject the tumor.We aimed to develop a lentivirus mediated gene transfer program incorporating a herpes simplex virus thymidine kinase(HSV-tk)in our dominant negative TGF-β type Ⅱ receptor(TβRⅡDNglytk)expression vector.So we first need to construct the lentiviral pLenti6/V5-D-TOPO vector containing TβRⅡDNglytk and produce the recombinant lentivirus as the transfection vector.Methods PCR were used to amplify the genes TβRⅡDN and HSV-tk from the respective plasmids.Then the genes were linked by recombinant PCR technology to construct the fusion gene TβRⅡDNglytk and control vector TRANSglytk.According to the operation manual from the Invitrogen company,TOPO cloning technology was used to construct the plasmids of pLenti6/V5-D-TOPO(R)-TβRⅡDNglytk and pLenti6/V5-D-TOPO(R)-TRANSglytk.Both of the constructed plasmids were verified by sequencing.ViraPowerTM Lentiviral System and 293 FT cells provided by Invitrogen were used to produce the recombinant lentivirus vector,the tillers of the lentivirus were determined by 293 cells.Results The construction of the plasmids of pLenti6/V5-D-TOPO(R)-TβRⅡDNglytk and pLenti6/V5-D-TOPO(R)-TRANSglytk were completed succefully.The DNA sequencing results showed that both the plasmids were constructed correctly.Using them we successfully produced infectious lentivirus vectors with appropriate tilters.Conclusions Using TOPO cloning technology in the construction of the plasmids of pLenti6/V5-D-TOPO(R)-TβRⅡDNglytk and pLenti6/V5-D-TOPO(R)-TRANSglytk and recombinant PCR in the fusion genes is feasible.Recombinant PCR combine with TOPO cloning technology can be a simple,highly efficient and rapid way to construct lentiviral vector.The production of infectious lentivirus with appropriate tilters using 293FT is suitable and feasible.The construction of pLenti6/V5-D-TOPO(R)-TβRⅡDNglytk and production of the infectious lentivirus will lay a foundation for immunotherapy of prostate cancer.
Keywords:Prostate Cancer  Lenti viral vector  Immunotherapy  Gene transfection
本文献已被 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号